Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
.26 x .28 (watch for break of .29)
a break above .29 could trigger a breakout run. Watching.
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=thphf&sid=0&o_symb=thphf&...
deal is non-convertable
the new financing as well as the old have all now been switched over to noin-convertable deals. Plus, Laurus cant sell until June 30, 2007....that gives THPHF a year to increase stock price which will only decrease dilution future.
TEDG (news) - ready for Flu season
China BioPharma Held Sales Meeting for the Upcoming Flu Season
ISELIN, N.J., Jul 12, 2006 (BUSINESS WIRE) -- Techedge Inc. (OTCBB:TEDG) announced that China BioPharma's subsidiary Zhejiang Tianyuan Biotech Co., held a successful sales meeting in Hangzhou, China last week with over 60 sales executives from all over the country were in attendance. The meeting addressed the vaccine demand and the company's sales plan in China for this year's flu vaccine sales season which starts this quarter.
China BioPharma has a distribution network throughout China covering most of the local provinces and major cities. Dr. Jean-Denis Shu, CEO of China BioPharma, Limited stated, "We have seen a strong demand of flu vaccines this year and our shipment of the flu vaccines is planned to start in August."
http://finance.yahoo.com/q?s=TEDG.OB
how is that toxic?
They are locked up and cant sell 1 shares until June 2007. But then THPHF could be at like .70 to 1.00+
but locked up till June 2007, right?
Those shares cant be sold until June 30, 2007....isnt that what the 8K said?
I agree that is a problem....
would like to see them establish a cap to those shares, but at least they are making moves to not massively dilute through bad financing like before.
Laurus restricted until June 2007
Company issued Laurus a warrant to purchase up to 1,810,674 shares of common stock at $.0001 per share. The original notes and New Note are secured by all of the Company's assets. Laurus is prohibited from selling any shares issuable upon exercise of the warrants until June 30, 2007
.26 x .27
could trigger a breakout if it breaks .29
THPHF .25 x .27 - breakout chart
If THPHF can break .29 it could trigger a run. Check out the chart and recent news.
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=thphf&sid=0&o_symb=thphf&...
TEDG - 2006 earnings projections out!!!
check out this report and projections from China BioPharma. Scroll to bottom of page for yearly projections.
NET INCOME
2006 = $1.1 million
2007 = $2.5 million
2008 = $5.4 million
REVENUE
2006 = $10 million
2007 = $20.5 million
2008 = $35.4 million
http://www.theasianinvestor.com/content/tedg_presentation.pdf
TEDG - 2006 earnings projections out
check out this report and projections from China BioPharma. Scroll to bottom of page for yearly projections.
NET INCOME
2006 = $1.1 million
2007 = $2.5 million
2008 = $5.4 million
REVENUE
2006 = $10 million
2007 = $20.5 million
2008 = $35.4 million
http://www.theasianinvestor.com/content/tedg_presentation.pdf
THPHF - .29 = breakout point
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=thphf&sid=0&o_symb=thphf&...
PRZ....short squeeze
PRZ chart
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=prz&sid=0&o_symb=prz&fre...
PRZ
short squeeze in motion. target $3.00+
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=prz&sid=0&o_symb=prz&fre...
PRZ
SHORT SQUEEZE!!!!!
http://finance.yahoo.com/q?s=PRZ
PRZ........SHORT SQUEEZE! (chart)
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=prz&sid=0&o_symb=prz&fre...
PRZ........SHORT SQUEEZE (chart)
PRZ ready to run back above $3.00+...take a look at the chart.
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=prz&sid=0&o_symb=prz&fre...
PRZ.........SHORT SQUEEZE!!!
- reported .17 EPS for Q1 (street was expecting .03 EPS)
- big short positions, heading back above $3.00
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=prz&sid=0&o_symb=prz&fre...
TEDG - .46 x .49 (up 25%)
http://finance.yahoo.com/q?s=TEDG.OB
PRZ .............SHORT SQUEEZE!!
Target short-term = $3.00
Target long-term $4.00 to $5.00
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=prz&sid=0&o_symb=prz&fre...
TEDG - .44 x .50 (up 25%....rockin)
China BioPharma (TEDG) - is one of China's largest human vaccine producer.
H5N1 vaccine research.
http://finance.yahoo.com/q?s=TEDG.OB
TEDG - gets Bird Flu virus
China BioPharma Receives Avian H5 Virus Strain, Begins Bird Flu Vaccine Research
NEW YORK--(WSNC)--June 28, 2006--TheAsianInvestor.com has learned directly from China BioPharma, Ltd. (OTCBB:TEDG) that the company has received a copy of the H5N1 virus from the NIBSC (National Institute for Biological Standard and Control) located in the UK.
From conversations with Dr. Shu, the CEO of China BioPharma, the Asian Investor has learned that the Company has received a copy of the Avian H5 virus from Britain’s NIBSC for the specific purpose of conducting research for a possible Avian 'Bird Flu' vaccine. The company has put together a five-member research team of scientists within the company for the purpose of this project, which will be headed up by Professor Zhi-Yong Zhu, the inventor of the China BioPharma's HFV (hemorrhagic fever vaccine).
Initial tests have begun at the company's new vaccine production facilities in China, with animal tests being conducted as we speak. The H5 virus strain was made inactive through the use of beta-propiolactone as opposed to formalin, which we usually use in vaccine research.
Dr. Shu commented to us , "Our companies main focus is, and has always been, the study, research, and creation of human vaccines for highly contagious and deadly diseases. With the growing threat of Avian H5N1 Bird Flu spreading through migrating birds, and now through Southeast Asia, such as with recent cases in Indonesia, we feel Professor Zhu to be the best person to lead this research project."
http://www.theasianinvestor.com/news/0628tedg.html
TEDG gets virus - (read this)
China BioPharma Receives Avian H5 Virus Strain, Begins Bird Flu Vaccine Research
NEW YORK--(WSNC)--June 28, 2006--TheAsianInvestor.com has learned directly from China BioPharma, Ltd. (OTCBB:TEDG) that the company has received a copy of the H5N1 virus from the NIBSC (National Institute for Biological Standard and Control) located in the UK.
From conversations with Dr. Shu, the CEO of China BioPharma, the Asian Investor has learned that the Company has received a copy of the Avian H5 virus from Britain’s NIBSC for the specific purpose of conducting research for a possible Avian 'Bird Flu' vaccine. The company has put together a five-member research team of scientists within the company for the purpose of this project, which will be headed up by Professor Zhi-Yong Zhu, the inventor of the China BioPharma's HFV (hemorrhagic fever vaccine).
Initial tests have begun at the company's new vaccine production facilities in China, with animal tests being conducted as we speak. The H5 virus strain was made inactive through the use of beta-propiolactone as opposed to formalin, which we usually use in vaccine research.
Dr. Shu commented to us , "Our companies main focus is, and has always been, the study, research, and creation of human vaccines for highly contagious and deadly diseases. With the growing threat of Avian H5N1 Bird Flu spreading through migrating birds, and now through Southeast Asia, such as with recent cases in Indonesia, we feel Professor Zhu to be the best person to lead this research project."
About China BioPharma
China BioPharma, which owns majority rights to Tianyuan Bio-pharmaceutical Co., Ltd., established in 1989, is one of China's largest non-governmental owned vaccine research manufacturers and is the first in China confirmed to GMP standard. The company's current products consist of vaccines for epidemic hemorrhagic fever (Ebola) and influenza with high reputation and market-occupying rate. The vaccines for both epidemic hemorrhagic fever and influenza virus have been awarded the National New Product Prize and National Tech Progress Prize.
Tianyuan Bio-pharmaceutical Co., Ltd. plans to establish the production of 3 to 5 new products to its research portfolio of vaccines, with 3 major in the series of aspects of bacterial, virus, and viral vaccines, having already accomplished a batch of technical achievements with autonomous intellectual property. With its recently completed production facility that is the largest and best human-vaccine production facility in China, it is also the nation's main vaccine production base whenever there is an epidemic disease outbreak in the region, such as SARS, and avian H5N1 influenza (bird flu). The company currently has around 140 employees. For more information on their current vaccines please visit www.ty-pharm.com
http://www.theasianinvestor.com/news/0628tedg.html
TEDG - major news
CHINA'S LARGEST VACCINE PRODUCER + DISTRIBUTOR MERGING
http://finance.yahoo.com/q?s=TEDG.OB
TEDG - China's largest vaccine distributor
China BioPharma (TEDG)
- Is one of China's largest human vaccine 'producer'
- Also acquiring China's laregst vaccine distributor
- producer + distributor = China's #1 biotech vaccine stock
http://finance.yahoo.com/q?s=TEDG.OB
Info on TEDG bird flu research
http://www.theasianinvestor.com/reports/tedg.htm
bird flu stocks (list)
List of stock conducting vaccine research into H5N1 avian Flu
http://www.ludlowcapital.com/reports/birdflu.htm
Bird Flu Stocks (list)
AVII AVI BioPharma, Inc. 3.89
GNBT Generex Biotechnology Corporation 1.47
GSK Glaxosmithkline Plc 53.84
HEB Hemispherx Biopharma, Inc 2.50
MEDI MedImmune, Inc. 29.78
NVAX Novavax, Inc. 4.71
SVA Sinovac Biotech Ltd 2.70
TEDG Techedge, Inc. Comm 0.51
VICL Vical Incorporated 5.94
http://www.ludlowcapital.com/reports/birdflu.htm
nice news
just have to spread the news around.
big news...zooom
TEDG - breakin 200 day MA (bird flu)
http://www.theasianinvestor.com/profile/tedg.htm
KEY HIGHLIGHTS TO CONSIDER
Human Vaccine Producer - the Company is one of China's largest non-governmental human vaccine producers. Their main focus is vaccines for highly contagious and deadly human diseases.
H5N1 Bird Flu Research - the Company has received a copy of the H5 virus strain from the NIBSC (National Institute for Biological Standard and Control), and has begun testing in animals.
Influenza Vaccine - the Company has a working Influenza vaccine already in the market, which can easily be paired with the H5N1 virus for a vaccine.
Chiron Vaccines - the Company has a number of ex-executives from Chiron Vaccines. The ex-President of Chiron Vaccines is on the Board of Advisors, and the CEO headed Chiron Vaccines China Division.
WHO and CDC Advisors - the Company also has a few Board of Advisors who have worked for the WHO, and China's CDC.
Revenues & Profitable - the Company did $9 million in vaccines sales for 2005, and turned a profit of around $1.5 million.
$1.31 Price Target - Ludlow Capital has a $1.31 price target on TEDG
TEDG - .53 x .55 (bird flu)
KEY HIGHLIGHTS ON TEDG
- Human Vaccine Producer - the Company is one of China's largest non-governmental human vaccine producers. Their main focus is vaccines for highly contagious and deadly human diseases.
- H5N1 Bird Flu Research - the Company has received a copy of the H5 virus strain from the NIBSC (National Institute for Biological Standard and Control), and has begun testing in animals.
- Influenza Vaccine - the Company has a working Influenza vaccine already in the market, which can easily be paired with the H5N1 virus for a vaccine.
- Chiron Vaccines - the Company has a number of ex-executives from Chiron Vaccines. The ex-President of Chiron Vaccines is on the Board of Advisors, and the CEO headed Chiron Vaccines China Division.
- WHO and CDC Advisors - the Company also has a few Board of Advisors who have worked for the WHO, and China's CDC.
- Revenues & Profitable - the Company did $9 million in vaccines sales for 2005, and turned a profit of around $1.5 million.
- $1.31 Price Target - Ludlow Capital has a $1.31 price target on TEDG
TEDG - highlights
KEY HIGHLIGHTS ON TEDG
- Human Vaccine Producer - the Company is one of China's largest non-governmental human vaccine producers. Their main focus is vaccines for highly contagious and deadly human diseases.
- H5N1 Bird Flu Research - the Company has received a copy of the H5 virus strain from the NIBSC (National Institute for Biological Standard and Control), and has begun testing in animals.
- Influenza Vaccine - the Company has a working Influenza vaccine already in the market, which can easily be paired with the H5N1 virus for a vaccine.
- Chiron Vaccines - the Company has a number of ex-executives from Chiron Vaccines. The ex-President of Chiron Vaccines is on the Board of Advisors, and the CEO headed Chiron Vaccines China Division.
- WHO and CDC Advisors - the Company also has a few Board of Advisors who have worked for the WHO, and China's CDC.
- Revenues & Profitable - the Company did $9 million in vaccines sales for 2005, and turned a profit of around $1.5 million.
- $1.31 Price Target - Ludlow Capital has a $1.31 price target on TEDG
TEDG - .53 x .55
TEDG - bird flu vaccine
China BioPharma (OTC:TEDG) - is one of China's largest non-governmental human vaccine production companies.
- $9 million in revenue
- $0.55 a share (.51 x .55)
- price target $1.31 (conservative)
READ THIS REPORT ON TEDG
http://www.theasianinvestor.com/reports/tedg.htm
TEDG - .52 x .56 (read report)
Read this report on China BioPharma (OTC:TEDG)
BIG UPSIDE HERE!
http://www.theasianinvestor.com/reports/tedg.htm
TEDG - receives PRC approval for merger.
TEDG - .52 x .56
China BioPharma (OTC:TEDG) - received approval from the PRC to finalize merger in the US. China BioPharma is one of China's largest non-governmental human vaccine producers.
The Company can produce up to 40 million vaccine doses incase of an emergency.
http://finance.yahoo.com/q?s=TEDG.OB
TEDG - .51 x .56
Ludlow Capital Issues $1.31 Price Target on TEDG on 'Bird Flu' Vaccine Acquisition
Research Staff
Last Update: May 19, 2006 - 7:45am EST
NEW YORK--May 19, 2006--Ludlow Capital establishes research coverage of TechEdge (OTC:TEDG), and their acquisition of China BioPharma Ltd., one of China's largest non-governmental vaccine production companies.
http://www.theasianinvestor.com/reports/tedg.htm
TEDG - running (chart)
China BioPharma (OTC:TEDG) - is one of China's largest human vaccine producers. they have copy of H5N1 virus in house.
LOOK AT CHART....RUNNING!!!!!
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=tedg&sid=0&o_symb=tedg&f...
awsome day
touched the 20 day MA....
Technically looking good, if they could hit with new or better yet audits we could have a perfect storm. Hope no ones short.
http://stockcharts.com/c-sc/sc?s=GRSR&p=D&b=5&g=0&i=t18915123202&r=5779